SeaCrest Wealth Management’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$380K Sell
757
-475
-39% -$228K 0.04% 359
2026
Q1
$606K Sell
1,232
-8
-0.6% -$4.34K 0.06% 280
2025
Q4
$765K Sell
1,240
-39
-3% -$22.1K 0.08% 234
2025
Q3
$686K Sell
1,279
-241
-16% -$112K 0.07% 248
2025
Q2
$616K Sell
1,520
-199
-12% -$83.2K 0.07% 266
2025
Q1
$856K Sell
1,719
-24
-1% -$13K 0.1% 203
2024
Q4
$907K Buy
1,743
+367
+27% +$202K 0.1% 199
2024
Q3
$851K Sell
1,376
-191
-12% -$113K 0.09% 219
2024
Q2
$867K Sell
1,567
-87
-5% -$49.8K 0.1% 202
2024
Q1
$961K Buy
1,654
+40
+2% +$22.4K 0.12% 185
2023
Q4
$857K Sell
1,614
-1
-0.1% -$484 0.11% 201
2023
Q3
$817K Sell
1,615
-10
-0.6% -$5.33K 0.11% 207
2023
Q2
$848K Sell
1,625
-22
-1% -$11.9K 0.11% 205
2023
Q1
$949K Buy
1,647
+273
+20% +$154K 0.13% 178
2022
Q4
$757K Buy
1,374
+11
+0.8% +$5.83K 0.11% 220
2022
Q3
$691K Sell
1,363
-19
-1% -$10.6K 0.1% 209
2022
Q2
$751K Sell
1,382
-183
-12% -$101K 0.09% 217
2022
Q1
$924K Sell
1,565
-61
-4% -$35K 0.11% 200
2021
Q4
$1.08M Buy
1,626
+31
+2% +$19.4K 0.12% 175
2021
Q3
$911K Sell
1,595
-28
-2% -$15.4K 0.11% 198
2021
Q2
$819K Buy
1,623
+28
+2% +$13.2K 0.1% 219
2021
Q1
$728K Buy
1,595
+24
+2% +$11.5K 0.1% 226
2020
Q4
$732K Sell
1,571
-109
-6% -$51.1K 0.1% 218
2020
Q3
$742K Sell
1,680
-24
-1% -$9.91K 0.12% 188
2020
Q2
$617K Sell
1,704
-12
-0.7% -$4.02K 0.11% 220
2020
Q1
$487K Buy
1,716
+92
+6% +$29K 0.1% 216
2019
Q4
$528K Buy
1,624
+187
+13% +$56.7K 0.09% 268
2019
Q3
$419K Buy
1,437
+105
+8% +$30.1K 0.08% 303
2019
Q2
$391K Buy
1,332
+10
+0.8% +$2.75K 0.08% 310
2019
Q1
$362K Sell
1,322
-170
-11% -$42.3K 0.06% 315
2018
Q4
$334K Sell
1,492
-288
-16% -$67.6K 0.07% 298
2018
Q3
$434K Buy
1,780
+609
+52% +$140K 0.07% 288
2018
Q2
$243K Buy
1,171
+28
+2% +$5.94K 0.04% 426
2018
Q1
$236K Buy
1,143
+118
+12% +$24.8K 0.04% 434
2017
Q4
$195K Buy
+1,025
New +$196K 0.04% 503

Other funds holding TMO

SeaCrest Wealth Management's TMO Position: Q2 2026 in Review

SeaCrest Wealth Management reduced its Thermo Fisher Scientific (TMO) stake by 39% in Q2 2026, selling an estimated $228K and leaving 757 shares worth $380K. The position accounts for 0.04% of the portfolio, ranked #359.

SeaCrest Wealth Management first reported a position in TMO in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.08M in Q4 2021. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • SeaCrest Wealth Management held 757 shares of Thermo Fisher Scientific worth $380K as of Q2 2026.
  • SeaCrest Wealth Management sold 475 Thermo Fisher Scientific shares in Q2 2026, an estimated $228K.
  • Thermo Fisher Scientific made up 0.04% of SeaCrest Wealth Management's portfolio in Q2 2026, its #359 holding.
  • SeaCrest Wealth Management first reported a position in Thermo Fisher Scientific in Q4 2017 and has held it in 35 quarters since.
  • SeaCrest Wealth Management's Thermo Fisher Scientific position peaked at $1.08M in Q4 2021.
  • 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on SeaCrest Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.